Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02581527
Other study ID # 15.0190
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 1, 2017
Est. completion date July 31, 2022

Study information

Verified date July 2022
Source St George's, University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater and faster killing of the tubercle bacillus in the lungs and result in relapse rates similar to those found in the World Health Organisation (WHO) recommended standard 6 month regimen.


Description:

Type of design An open-label 3-arm trial to compare a standard 6-month control regimen with two 4-month treatment regimens for the treatment of tuberculosis (TB). Disease/patients studied The trial will include 654 patients newly diagnosed with pulmonary TB with sputum positive or negative for TB on microscopy but with a positive result on a GeneXpert Test with organisms fully sensitive to rifampicin The treatment regimens - Control and Experimental Patients enrolled in the trial will be randomly allocated to receive one of the following three chemotherapy treatment regimens: 1. Control regimen (R10): The standard regimen of isoniazid, pyrazinamide and ethambutol plus 10 mg/kg rifampicin for the initial 8 weeks, followed by isoniazid and rifampicin (at the same dose size) for an additional 4 months (2HRZE/4HR)A. 2. Study regimen 1(SR1): 2 months of daily ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin. A supplement of either 450 mg (weight bands 35-39kg and 40-54kg) or 600mg (weight band 55-69kg and 70 and more kg) of rifampicin will be given throughout the four months (2EHR 1200Z/2HR1200)B. 3. Study regimen 2(SR2): 2 months of daily ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 2 months of daily isoniazid and rifampicin. A supplement of either 450 mg (weight bands 35-39kg and 40-54kg) or 600mg (weight band 55-69kg and 70 and more kg) of rifampicin will be given throughout the four months (2EHR1800Z/2HR1800)C. 1.1 Outcome measures Primary outcome measure 1. Since the objective of the trial is to reduce treatment duration by increasing the dose of rifampicin, the primary outcome measure is the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients. 2. The occurrence of grade 3 or 4 adverse events at any time during chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 672
Est. completion date July 31, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. GeneXpert sputum positive, rifampicin susceptible, newly diagnosed pulmonary tuberculosis will be included even if they are microscopy negative. 2. No previous anti-tuberculosis chemotherapy. 3. Patients = 18 years 4. Consent to participation in the trial and to HIV testing 5. Provide informed consent. 6. Patient has a stable home address within easy reach of the treatment facility and likely to remain there for the next 18 months. 7. Pre-menopausal women must be using a barrier form of contraception or be surgically sterilised or have an Intrauterine Contraceptive Device (IUCD) in place for the duration of the treatment phase Exclusion Criteria: 1. Patients with rifampicin resistance identified by GeneXpert or by direct susceptibility testing (late exclusions). 2. Has any condition that may prove fatal during the study period. 3. Has TB meningitis. 4. Has pre-existing non-tuberculous disease likely to prejudice the response to, or assessment of, treatment e.g. insulin-dependent diabetes, liver or kidney disease, blood disorders, peripheral neuritis, and severe thrombocytopenia, rash, increase of bilirubin and other diseases that are likely to be contraindicated with rifampicin 5. Is female and known to be pregnant, or breast feeding. 6. Is suffering from a condition likely to lead to uncooperative behaviour such as psychiatric illness or alcoholism. 7. Has contraindications to any medications in the study regimens 8. Is HIV positive 9. Haemoglobin <7g/l 10. Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 5 times the upper limit of normal (ULN) for that laboratory 11. Creatinine clearance (CrCl) of < 30mls/min. Calculated as CrCl (mL/min) = N x [140-age (years)] x weight (kg) Serum creatinine (micromol/L) Where N = 1.23 males, 1.04 females 12. Has glucose in urine 13. Weight < 35kg

Study Design


Intervention

Drug:
Rifampicin
Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
Isoniazid
Isoniazid 75mg - all arms
Ethambutol
Ethambutol 275mg - all arms
Pyrazinamide
Pyrazinamide 400mg - all arms

Locations

Country Name City State
Botswana University of Botswana Gaborone
Guinea Hopital National Ignace Deen Conakry
Nepal GENETUP, National Anti-TB Association Kathmandu
Pakistan Aga Khan University Hospital Karachi
Peru Hospital Nacional Dos de Mayo Lima
Uganda Epicentre Mbarara

Sponsors (3)

Lead Sponsor Collaborator
St George's, University of London London School of Hygiene and Tropical Medicine, University of Botswana

Countries where clinical trial is conducted

Botswana,  Guinea,  Nepal,  Pakistan,  Peru,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary The occurrence of grade 3 or 4 adverse events at any time during chemotherapy. 18 months
Primary the primary outcome measure is the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients in the modified intent to treat population. 18 months
Secondary Sputum cultures positive for M.tuberculosis at 8 and 12 weeks from randomisation. 18 months
Secondary Per protocol analysis of the primary efficacy outcome (the combined rate of failure at the end of treatment and relapse during the subsequent 12 months in smear positive patients) 18 months
Secondary Combined unfavourable endpoint (rate of failure at the end of treatment and relapse) measured 18 months from randomisation in the Xpert MTB/RIF positive (i) modified intent-to-treat and (ii) per protocol populations 18 months
Secondary Any adverse event, up to one month after completion of treatment, graded according to the DAIDS criteria 1 month after end of treatment (7 months (Control), 5 months (Study regimens) )
Secondary Time to unfavourable outcome in the modified intent-to-treat and per protocol sputum smear microscopy-positive population. 18 Months
See also
  Status Clinical Trial Phase
Completed NCT02736864 - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae N/A
Not yet recruiting NCT04055441 - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed NCT02349841 - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis Phase 2
Completed NCT01927159 - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers Phase 1
Active, not recruiting NCT01691534 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) Phase 2
Completed NCT00803322 - Improving Community Based Tuberculosis Care in Ethiopia Phase 4
Completed NCT00834353 - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis N/A
Withdrawn NCT03277742 - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz N/A
Completed NCT00057434 - Vitamin A Therapy for Tuberculosis Phase 3
Not yet recruiting NCT06192160 - Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Phase 2
Recruiting NCT06127641 - Rehabilitation of People With Post-tuberculosis Lung Disease N/A
Recruiting NCT06058299 - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis Phase 2
Completed NCT04550832 - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Phase 2
Completed NCT02912832 - Prospective Assessment of TBDx Feasibility N/A
Completed NCT01215851 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) Phase 2
Recruiting NCT01503099 - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease N/A
Completed NCT04608955 - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 Phase 2
Recruiting NCT05046366 - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed NCT05896930 - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis Phase 2
Completed NCT02279875 - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) Phase 2